NeoNotes Journal Club
Andrew B. Kairalla MD, Editor
4-012 | Additional Comments | Previous Article | Next Article | Search | List of Articles | Submit Comments | Index | FSN Home Page
Objective. Treatment of posthemorrhagic ventricular dilation in premature infants is fraught with failures and complications. We have piloted a new treatment aimed at removing intraventricular blood and the cytokines associated with hydrocephalus.
Methods. Twenty-four infants were enrolled with ventricular width enlarged to 4 mm over the 97th centile after a large intraventricular hemorrhage. Sixteen had parenchymal brain lesions before treatment. Median gestation was 28 weeks, and birth weight was 1150 g. At a median postnatal age of 17 days, 2 ventricular catheters (1 right frontal, 1 left occipital) were inserted with 13 infants also having a reservoir frontally. Tissue plasminogen activator 0.5 mg/kg was given intraventricularly 8 hours before the ventricles were irrigated with artificial cerebrospinal fluid at 20 mL/h for a median of 72 hours.
Results. Seventeen of 23 survivors (74%) did not require a ventriculoperitoneal shunt. One infant (of 23 weeks’ gestation) died. Two infants developed reservoir-associated infection, and 2 infants had a second intraventricular hemorrhage. Of the 19 survivors aged >12 months postterm, 8 were normal, 7 (37%) had single disability, and 4 (21%) had multiple disabilities.
Conclusions. Shunt surgery was reduced compared with historical controls with similar treatment criteria. Mortality and single and multiple disability rates all showed downward trends. Reducing pressure, free iron, and proinflammatory and profibrotic cytokines may reduce periventricular brain damage and permanent hydrocephalus. Additional advances will require a controlled trial and better knowledge of the mechanisms of hydrocephalus.
Comment:
This aggressive new
treatment for post-hemorrhagic hydrocephalus is called “DRIFT” (drainage,
irrigation and fibrinolytic therapy). For
those of us who have been frustrated by the failure of less-aggressive
treatments for this condition, DRIFT offers exciting possibilities.
The treatment is labor-intensive (requiring 1:1 nursing), and certainly
not without risks. We now need a
large randomized, controlled trial of DRIFT vs conventional therapy to confirm
the efficacy of this approach. ABK
Additional Comments: You may add your own comments to the discussion of this topic by selecting : Submit Comments.